181 lines
64 KiB
Text
181 lines
64 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548231">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548231/?report=reader">
|
|
<meta name="ncbi_pagename" content="Kratom - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Kratom - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Khat/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Labetalol/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Kratom">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2020/04/03">
|
|
<meta name="citation_pmid" content="31643556">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548231/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Kratom">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2020/04/03">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548231/">
|
|
<meta name="description" content="Kratom is an herbal made from leaves of a tropical evergreen tree (Mitragyna speciosa) that is native to Southeast Asia. Extracts from the leaves of the kratom tree have psychotropic and opioid-like activity, which has led to their use as a recreational drug. Kratom has been linked to rare instances of clinically apparent acute liver injury.">
|
|
<meta name="og:title" content="Kratom">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Kratom is an herbal made from leaves of a tropical evergreen tree (Mitragyna speciosa) that is native to Southeast Asia. Extracts from the leaves of the kratom tree have psychotropic and opioid-like activity, which has led to their use as a recreational drug. Kratom has been linked to rare instances of clinically apparent acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548231/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Kratom/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548231/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C62937D7D52310000000000A60086.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548231/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Khat/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Kratom</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Labetalol/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548231/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548231/&text=Kratom"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548231/?report=classic">Switch to classic view</a><a href="/books/NBK548231/pdf/Bookshelf_NBK548231.pdf">PDF (373K)</a><a href="/books/NBK548231/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548231%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C62937D7D52310000000000A60086.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548231_"><span class="title" itemprop="name">Kratom</span></h1><p class="fm-aai"><a href="#_NBK548231_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Kratom.OVERVIEW"><h2 id="_Kratom_OVERVIEW_">OVERVIEW</h2><div id="Kratom.Introduction"><h3>Introduction</h3><p>Kratom is an herbal made from leaves of a tropical evergreen tree (Mitragyna speciosa) that is native to Southeast Asia. Extracts from the leaves of the kratom tree have psychotropic and opioid-like activity, which has led to their use as a recreational drug. Kratom has been linked to rare instances of clinically apparent acute liver injury.</p></div><div id="Kratom.Background"><h3>Background</h3><p>Kratom is a botanical extract derived from the leaves of a tropical evergreen tree (Mitragyna speciosa), which belongs to the coffee family and is indigenous to Thailand, Myanmar and Malaysia. In Southeast Asia, kratom has been used for decades as an herbal medication to treat chronic pain, increase energy and stamina, treat chronic pain and diarrhea, and as a substitute for opium or for opium withdrawal. The leaves have multiple components, including psychoactive alkaloids that have opioid-like activity. In many Southeast Asian countries, chewing Mitragyna speciosa leaves is a not uncommon practice and not considered addictive. The effects of chewing kratom leaves include enhanced alertness, talkativeness and sociability. Extracts of kratom have been used to treat chronic pain, diarrhea and cough. The psychoactive effects of kratom have led to its use recreationally as a cannabis-like drug. Higher doses can cause agitation, hypertension, dyspnea and confusion. Overdoses of kratom can cause seizures, coma and death. Kratom has become a substance of abuse and it has not been shown to have any beneficial medical uses. The US FDA and the Drug Enforcement Agency have put out notices of concern about use of kratom as a dietary supplement because of safety issues, including adverse effects of respiratory depression, aggression, hallucinations, delusions, insomnia, vomiting and severe withdrawal. Despite these warnings and lack of known medical benefits, kratom has become a popular and widely available herbal product used for opiate withdrawal symptoms and musculoskeletal pain. Several deaths from kratom overdose have been reported.</p></div><div id="Kratom.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Chronic use of kratom recreationally has been associated with rare instances of acute liver injury. The onset of injury is usually within 1 to 8 weeks of starting regular use of kratom powder or tablets, with symptoms of fatigue, nausea, pruritus and dark urine followed by jaundice. The pattern of liver injury is typically cholestatic or mixed, and it can be severe with serum bilirubin levels rising above 20 mg/dL. The severe cholestasis can be accompanied by acute renal failure and bone marrow toxicity. Fever is common, but not rash or eosinophilia and autoantibodies are usually absent. The cholestasis can be prolonged, but usually resolves spontaneously. Corticosteroids as well as N-acetylcysteine have been used in cases of suspected kratom hepatotoxicity, but their efficacy is unproven. Kratom is a banned substance in many areas of the country and considered an agent of abuse rather than a dietary supplement. At least two dozen cases of clinically apparent liver injury with jaundice have been reported in the literature and a similar number reported to the Food and Drug Administration adverse event database.</p><p>Likelihood Score: B (likely cause of clinically apparent liver injury).</p></div><div id="Kratom.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of liver injury due to kratom is unknown. It is often used with other agents, including drugs of abuse, and its causative relationship to liver injury in published cases is not always clear.</p></div><div id="Kratom.Outcome_and_Management"><h3>Outcome and Management</h3><p>Patients who present with acute liver injury due to kratom usually recover once it is discontinued. There is no evidence that corticosteroids shorten the course of illness or improve outcomes. Patients should be warned against further use of kratom and multiingredient nutrition supplements that might contain it.</p><p>Drug Class: <a href="/books/n/livertox/HerbalDietarySuppl/?report=reader">Herbal and Dietary Supplements</a></p></div></div><div id="Kratom.PRODUCT_INFORMATION"><h2 id="_Kratom_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Kratom – Generic</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Herbal and Dietary Supplements</p><p>SUMMARY INFORMATION</p><p>
|
|
<a href="https://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fact Sheet at DEA, Office of Diversion Control, Drug & Chemical Evaluation Section</a>
|
|
</p></div><div id="Kratom.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Kratom_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figKratomTc"><a href="/books/NBK548231/table/Kratom.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobKratomTc"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Kratom.Tc"><a href="/books/NBK548231/table/Kratom.Tc/?report=objectonly" target="object" rid-ob="figobKratomTc">Table</a></h4></div></div></div><div id="Kratom.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Kratom_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 05 April 2020</p><p>Abbreviations: HDS, herbal and dietary supplements.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Kratom.REF.zimmerman.1999">Zimmerman HJ. Unconventional drugs. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 731-4.<div><i>(Expert review of hepatotoxicity published in 1999; kratom is not discussed).</i></div></div></li><li><div class="bk_ref" id="Kratom.REF.seeff.2013">Seeff L, Stickel F, Navarro VJ. Hepatotoxicity of herbals and dietary supplements. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 631-58.<div><i>(Review of hepatotoxicity of herbal and dietary supplements [HDS]; kratom is not discussed).</i></div></div></li><li><div class="bk_ref" id="Kratom.REF3">Drug Enforcement Administration. Kratom (Mitragyna speciosa korth). <a href="https://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.deadiversion<wbr style="display:inline-block"></wbr>​.usdoj.gov/drug_chem_info/kratom.pdf</a>.<div><i>(Short description of the chemistry, mechanism of action and potential for abuse and harm from kratom by the Drug Enforcement Administration).</i></div></div></li><li><div class="bk_ref" id="Kratom.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network(DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div>
|
|
<i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 9% were attributed to herbals and dietary supplements, but none to kratom).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20949552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div>
|
|
<i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, including 12 [9%] attributed to herbals, but none to kratom).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.nelsen.2010.424">Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following Kratom(Mitragynina speciosa Korth) exposure. <span><span class="ref-journal">J Med Toxicol. </span>2010;<span class="ref-vol">6</span>:424–6.</span> [<a href="/pmc/articles/PMC3550469/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3550469</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20411370" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20411370</span></a>]<div>
|
|
<i>(64 year old man developed seizures and coma shortly after ingesting kratom tea and datura stramonium [Jimson weed with anticholinergic activity], having high levels of both in urine, awaking after 24 hours and admitting to chronic use of kratom for chronic pain).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.ward.2011.999">Ward J, Rosenbaum C, Hernon C, McCurdy CR, Boyer EW. Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? <span><span class="ref-journal">CNS Drugs. </span>2011;<span class="ref-vol">25</span>:999–1007.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22133323" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22133323</span></a>]<div>
|
|
<i>(Review of herbal medications that are used for opioid addiction and withdrawal; there have been no formal trials of the efficacy and safety of kratom for withdrawal symptoms).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.kapp.2011.227">Kapp FG, Maurer HH, Auwärter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). <span><span class="ref-journal">J Med Toxicol. </span>2011;<span class="ref-vol">7</span>:227–31.</span> [<a href="/pmc/articles/PMC3550198/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3550198</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21528385" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21528385</span></a>]<div>
|
|
<i>(25 year old man developed fever and abdominal pain followed by jaundice a week after stopping a 2 week course of kratom powders [bilirubin 31.9 mg/dL, ALT 94 U/L, Alk P 173 U/L], liver biopsy showing bland cholestasis, with slow and spontaneous improvement).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.schmidt.2011.92">Schmidt MM, Sharma A, Schifano F, Feinmann C. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. <span><span class="ref-journal">Forensic Sci Int. </span>2011;<span class="ref-vol">206</span>:92–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20650576" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20650576</span></a>]<div>
|
|
<i>(Internet searches for "legal highs" identified several hundred websites offering various products [pills, smoking materials, powders, teas], 92% of which did not list ingredients and 92% failing to mention side effects, most common products being Salvia divinorum and kratom).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.kronstrand.2011.242">Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. <span><span class="ref-journal">J Anal Toxicol. </span>2011;<span class="ref-vol">35</span>:242–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21513619" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21513619</span></a>]<div>
|
|
<i>(9 cases of fatal overdose of "Krypton" were identified over a 1 year period [2009-2010] in Sweden; 7 men and 2 women, ages 22 to 35 years, found dead or presenting in shock and asystole with lung and brain edema in all and liver steatosis in one; Krypton consists of powder extracts of kratom leaves and the mu-opioid agonist, O-desmethyltramadol, the major active metabolite of tramadol).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.holler.2011.54">Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J Jr, Solomon CJ, Levine B. A drug toxicity death involving propylhexedrine and mitragynine. <span><span class="ref-journal">J Anal Toxicol. </span>2011;<span class="ref-vol">35</span>:54–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21219704" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21219704</span></a>]<div>
|
|
<i>(20 year old man was found dead with no signs of trauma, but a history of kratom ingestion and autopsy showing pulmonary edema and presence of propylhexedrine, and kratom in urine).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.rosenbaum.2012.15">Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. <span><span class="ref-journal">J Med Toxicol. </span>2012;<span class="ref-vol">8</span>:15–32.</span> [<a href="/pmc/articles/PMC3550220/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3550220</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22271566" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22271566</span></a>]<div>
|
|
<i>(Review of herbal alternatives to marijuana for euphoric effects, including kratom which has stimulatory effects at low doses and opioid-like effects at higher doses, and is available through the internet as powders, leaves, teas or as tablets, sometimes combined with other opiate-like agents).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.prozialeck.2012.792">Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. <span><span class="ref-journal">J Am Osteopath Assoc. </span>2012;<span class="ref-vol">112</span>:792–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23212430" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23212430</span></a>]<div>
|
|
<i>(Concise review of chemical constituents, pharmacology, clinical effects, uses and safety of kratom).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.forrester.2013.396">Forrester MB. Kratom exposures reported to Texas poison centers. <span><span class="ref-journal">J Addict Dis. </span>2013;<span class="ref-vol">32</span>:396–400.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24325774" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24325774</span></a>]<div>
|
|
<i>(Between 2009 and 2013, there were 14 reports of kratom exposures to the Texas Poison center, but none between 1998 and 2008; adverse events being tachycardia, agitation, nausea, vomiting, tremor, sweating, diaphoresis, drowsiness and hallucinations but no deaths).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.neerman.2013.s278">Neerman MF, Frost RE, Deking J. A drug fatality involving Kratom. <span><span class="ref-journal">J Forensic Sci. </span>2013;<span class="ref-vol">58</span> Suppl 1:S278–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23082895" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23082895</span></a>]<div>
|
|
<i>(17 year old man was found dead with empty bottles and boxes of kratom, autopsy showing bilateral pulmonary edema and high mitragynine blood levels).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.ulbricht.2013.152">Ulbricht C, Costa D, Dao J, Isaac R, LeBlanc YC, Rhoades J, Windsor RC. An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration. <span><span class="ref-journal">J Diet Suppl. </span>2013;<span class="ref-vol">10</span>:152–70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23725528" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23725528</span></a>]<div>
|
|
<i>(Systematic review of safety and efficacy of kratom [Mitragyna speciosa] concludes that there is a lack of evidence in support of kratom having any clinical indication, its historic uses being as an analgesic, antitussive, anxiolytic, and treatment for opiate withdrawal).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.singh.2014.132">Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. <span><span class="ref-journal">Drug Alcohol Depend. </span>2014;<span class="ref-vol">139</span>:132–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24698080" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24698080</span></a>]<div>
|
|
<i>(Survey of kratom abuse among 293 Malaysian men, who typically used it 3 times daily, to improve energy, treat pain or avoid opiate use; most were dependent and had a history of withdrawal symptoms if they tried to stop).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.teschke.2013.1093">Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C. Herbal hepatotoxicity: suspected cases assessed for alternative causes. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2013;<span class="ref-vol">25</span>:1093–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23510966" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23510966</span></a>]<div>
|
|
<i>(Review of the literature of case series of suspected HDS related liver injury found evidence of other explanations for the liver injury in 19 of 23 publications involving 278 of 573 patients [49%], and that these other diagnoses weakened the causality assessment in most instances).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.bj_rnsson.2013.1419">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div>
|
|
<i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period [2010-2011], including 15 [16%] due to herbal and dietary supplements, but none were attributed to kratom).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.navarro.2014.1399">Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. <span><span class="ref-journal">Hepatology. </span>2014;<span class="ref-vol">60</span>:1399–408.</span> [<a href="/pmc/articles/PMC4293199/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4293199</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25043597" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25043597</span></a>]<div>
|
|
<i>(Among 85 cases of HDS associated liver injury [not due to anabolic steroids] enrolled in a US prospective study between 2004 and 2013, the single most commonly implicated herbal agent was green tea extract, two cases occurred in patients taking kratom, although in both instances along with other potential hepatotoxic products).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.navarro.2014.172">Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. <span><span class="ref-journal">Semin Liver Dis. </span>2014;<span class="ref-vol">34</span>:172–93.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24879982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24879982</span></a>]<div>
|
|
<i>(Review of HDS induced liver injury including regulatory problems, difficulties in diagnosis and causality assessment; kratom is not discussed).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.seeff.2015.517">Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:517–532.e3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25500423" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25500423</span></a>]<div>
|
|
<i>(Extensive review of possible beneficial as well as harmful effects of herbal products on the liver; kratom is not discussed).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.stickel.2015.851">Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. <span><span class="ref-journal">Arch Toxicol. </span>2015;<span class="ref-vol">89</span>:851–65.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25680499" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25680499</span></a>]<div>
|
|
<i>(Extensive review of liver injury due to HDS, but kratom is not discussed).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div>
|
|
<i>(Among 899 cases of drug induced liver injury enrolled in a prospective database between 2004 and 2012, HDS were implicated in 145 [16%], the single major herbal cause being green tea extract but kratom was mentioned among products taken by two subjects with liver injury).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.dorman.2015.1086">Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: a case report. <span><span class="ref-journal">Hepatology. </span>2015;<span class="ref-vol">61</span>:1086–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25418457" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25418457</span></a>]<div>
|
|
<i>(58 year old man developed jaundice 3 months after starting kratom powder for anxiety [bilirubin 9.7 mg/dL, ALT 79 U/L, Alk P 270 U/L], which resolved upon stopping and recurred one year later 1 month after he restarted kratom [bilirubin 25.6 mg/dL, ALT 106 U/L, Alk P 790 U/L], improving again upon stopping but he was lost to follow up before full recovery was documented).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.mcintyre.2015.152">McIntyre IM, Trochta A, Stolberg S, Campman SC. Mitragynine 'Kratom' related fatality: a case report with postmortem concentrations. <span><span class="ref-journal">J Anal Toxicol. </span>2015;<span class="ref-vol">39</span>:152–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25516573" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25516573</span></a>]<div>
|
|
<i>(24 year old man with depression and alcoholism was found dead in bed, postmortem toxicology showing high plasma levels of mitragynine [kratom], but only therapeutic levels of his medications [venlafaxine, mirtazapine, diphenhydramine], liver autopsy histology not mentioned).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.warner.2016.127">Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. <span><span class="ref-journal">Int J Legal Med. </span>2016;<span class="ref-vol">130</span>:127–38.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26511390" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26511390</span></a>]<div>
|
|
<i>(Review of the pharmacology and toxicology of kratom, its widespread abuse [even among high school students], its present legal situation which is complicated by variations in restrictions from state to state resulting in its continued availability "via head shops, kava bars and especially the Internet").</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.garc_acort_s.2016.537">García-Cortés M, Robles-Díaz M, Ortega-Alonso A, Medina-Caliz I, Andrade RJ. Hepatotoxicity by dietary supplements: A tabular listing and clinical characteristics. <span><span class="ref-journal">Int J Mol Sci. </span>2016;<span class="ref-vol">17</span>:537.</span> [<a href="/pmc/articles/PMC4848993/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4848993</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27070596" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27070596</span></a>]<div>
|
|
<i>(Listing of published cases of liver injury from HDS products, does not mention kratom).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.avigan.2016.331">Avigan MI, Mozersky RP, Seeff LB. Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. <span><span class="ref-journal">Int J Mol Sci. </span>2016;<span class="ref-vol">17</span>:331.</span> [<a href="/pmc/articles/PMC4813193/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4813193</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26950122" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26950122</span></a>]<div>
|
|
<i>(Overview of the US regulations regarding herbal and dietary supplements and role of FDA, Department of Agriculture, Federal Trade Commission and Office of Dietary Supplements of the NIH in assessment of safety of HDS products including actions taken against Hydroxycut, Lipokinetix and OxyELITE Pro when reports of liver injury appeared in postmarketing phase).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.marcus.2016.410">Marcus DM. Dietary supplements: What's in a name? What's in the bottle? <span><span class="ref-journal">Drug Test Anal. </span>2016;<span class="ref-vol">8</span>(3-4):410–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27072845" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27072845</span></a>]<div>
|
|
<i>(Commentary on regulation of HDS products concludes: "the marketing of botanical supplements is based on unfounded claims that they are safe and effective", and "there is no reason to take herbal medicines whose composition and benefits are unknown and whose risks are evident").</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.pantano.2016.580">Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, Terranova D. Bet al. Hepatotoxicity induced by "the 3Ks": kava, kratom and khat. <span><span class="ref-journal">Int J Mol Sci. </span>2016;<span class="ref-vol">17</span>:580.</span> [<a href="/pmc/articles/PMC4849036/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4849036</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27092496" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27092496</span></a>]<div>
|
|
<i>(Review of the published literature on the clinical features and pathogenesis of liver injury associated with three herbals – kava, kratom and khat).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.brown.2017">Brown AC. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series. Food Chem Toxicol 2017; 107 (Pt A): 449-71. [<a href="https://pubmed.ncbi.nlm.nih.gov/27818322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27818322</span></a>]<div><i>(Summary of the US regulations on safety and efficacy of herbal and dietary supplements).</i></div></div></li><li><div class="bk_ref" id="Kratom.REF.brown.2017_1">Brown AC. Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series. Food Chem Toxicol 2017; 107 (Pt A): 472-501. [<a href="https://pubmed.ncbi.nlm.nih.gov/27402097" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27402097</span></a>]<div><i>(Description of an online compendium of cases of liver toxicity attributed to HDS products, lists published cases for multiple agents, but kratom is not mentioned).</i></div></div></li><li><div class="bk_ref" id="Kratom.REF.wong.2017.322">Wong LL, Lacar L, Roytman M, Orloff SL. Urgent liver transplantation for dietary supplements: an under-recognized problem. <span><span class="ref-journal">Transplant Proc. </span>2017;<span class="ref-vol">49</span>:322–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28219592" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28219592</span></a>]<div>
|
|
<i>(Among 2048 adult liver transplants recipients enrolled in the Scientific Registry of Transplant Recipients [SRTR] between 2003 and 2015, 625 were done for acute hepatic necrosis due to drug induced liver injury, half being due to acetaminophen and the 4th most frequent cause [n=21] being HDS products).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.vega.2017.783">Vega M, Verma M, Beswick D, Bey S, Hossack J, Merriman N, Shah A, et al. Drug Induced Liver Injury Network (DILIN). The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. <span><span class="ref-journal">Drug Saf. </span>2017;<span class="ref-vol">40</span>:783–7.</span> [<a href="/pmc/articles/PMC5699929/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5699929</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28555362" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28555362</span></a>]<div>
|
|
<i>(A prospective, population based registry of cases of drug induced liver injury occurring in Delaware during 2014, identified 20 cases [2.7 per 100,000] overall, including 6 due to HDS products, all of which were proprietary multiingredient products, none of them mentioning kratom as a component).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.navarro.2017.363">Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. <span><span class="ref-journal">Hepatology. </span>2017;<span class="ref-vol">65</span>:363–73.</span> [<a href="/pmc/articles/PMC5502701/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5502701</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27677775" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27677775</span></a>]<div>
|
|
<i>(Review of the problems of liver injury and HDS products and challenges for future research concludes that stronger regulations are needed to address the increasing number of cases of HDS induced liver injury, particularly those linked to use of multiingredient dietary supplements).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.tayabali.2018.107">Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. <span><span class="ref-journal">J Community Hosp Intern Med Perspect. </span>2018;<span class="ref-vol">8</span>:107–110.</span> [<a href="/pmc/articles/PMC5998276/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5998276</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29915645" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29915645</span></a>]<div>
|
|
<i>(32 year old man developed jaundice after taking 60 tablets of kratom over one week for low back pain [bilirubin 6.3 mg/dL, ALT 365 U/L, Alk P 391 U/L], liver tests improving over the week following discontinuation).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.riverso.2018.79">Riverso M, Chang M, Soldevila-Pico C, Lai J, Liu X. Histologic characterization of kratom use-associated liver injury. <span><span class="ref-journal">Gastroenterology Res. </span>2018;<span class="ref-vol">11</span>:79–82.</span> [<a href="/pmc/articles/PMC5827910/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5827910</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29511414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29511414</span></a>]<div>
|
|
<i>(36 year old man developed dark urine while taking kratom [bilirubin 5.1 mg/dL, ALT 389 U/L, Alk P 304 U/L], which improved after stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.mousa.2018.e550">Mousa MS, Sephien A, Gutierrez J. OʼLeary C. N-Acetylcysteine for acute hepatitis induced by kratom herbal tea. <span><span class="ref-journal">Am J Ther. </span>2018;<span class="ref-vol">25</span>:e550–e551.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28708700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28708700</span></a>]<div>
|
|
<i>(31 year old man developed fever, fatigue and jaundice after drinking kratom tea daily for 2 weeks for opiate withdrawal symptoms [bilirubin 2.2 mg/dL, ALT 578 U/L, Alk P 191 U/L], given N-acetylcysteine and recovered with normal liver tests 2 months later).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.white.2018.261">White CM. Pharmacologic and clinical assessment of kratom. <span><span class="ref-journal">Am J Health Syst Pharm. </span>2018;<span class="ref-vol">75</span>:261–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29255059" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29255059</span></a>]<div>
|
|
<i>(Review of the pharmacology and clinical effects of kratom, stressing its opioid agonist effects and abuse potential and that at least 36 deaths have been attributed to its use [usually overdose] as well as at least one case of cholestatic hepatitis).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.riverso.2018.79_1">Riverso M, Chang M, Soldevila-Pico C, Lai J, Liu X. Histologic characterization of kratom use-associated liver injury. <span><span class="ref-journal">Gastroenterology Res. </span>2018;<span class="ref-vol">11</span>:79–82.</span> [<a href="/pmc/articles/PMC5827910/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5827910</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29511414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29511414</span></a>]<div>
|
|
<i>(38 year old man developed fever followed by dark urine and jaundice while taking kratom [bilirubin 5.1 mg/dL, ALT 389 U/L, Alk P 304 U/L]; a liver biopsy showed acute cholestatic hepatitis, and he improved rapidly upon stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.aldyab.2019.211">Aldyab M, Ells PF, Bui R, Chapman TD, Lee H. Kratom-induced cholestatic liver injury mimicking anti-mitochondrial antibody-negative primary biliary cholangitis: a Case Report and Review of Literature. <span><span class="ref-journal">Gastroenterology Res. </span>2019;<span class="ref-vol">12</span>:211–5.</span> [<a href="/pmc/articles/PMC6731044/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6731044</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31523332" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31523332</span></a>]<div>
|
|
<i>(40 year old woman developed fever and abdominal pain after taking kratom once weekly for 4 weeks [bilirubin 5.1 mg/dL, ALT 875 U/L, Alk P 162 U/L], resolving within 5 weeks of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.fernandes.2019.2324709619836138">Fernandes CT, Iqbal U, Tighe SP, Ahmed A. Kratom-induced cholestatic liver injury and its conservative management. <span><span class="ref-journal">J Investig Med High Impact Case Rep. </span>2019;<span class="ref-vol">7</span>:2324709619836138. </span> [<a href="/pmc/articles/PMC6440031/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6440031</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30920318" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30920318</span></a>]<div>
|
|
<i>(52 year old man developed fatigue and jaundice several weeks after stopping a 2 month course of kratom for joint pain [bilirubin 23.2 mg/dL, ALT 66 U/L, Alk P 255 U/L], resolving over the following several weeks).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.osborne.2019.2324709619826167">Osborne CS, Overstreet AN, Rockey DC, Schreiner AD. Drug-induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic. <span><span class="ref-journal">J Investig Med High Impact Case Rep. </span>2019;<span class="ref-vol">7</span>:2324709619826167. </span> [<a href="/pmc/articles/PMC6350132/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6350132</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30791718" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30791718</span></a>]<div>
|
|
<i>(47 year old man developed fever, fatigue and dark urine 3 weeks after starting kratom for pain [bilirubin 5.8 mg/dL, ALT 265 U/L, Alk P 180 U/L] and had a recurrence 9 months later within days of restarting [bilirubin 3.2 mg/dL, ALT 566 U/L, Alk P 211 U/L]).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.palasamudram_shekar.2019.28">Palasamudram Shekar S, Rojas EE, D'Angelo CC, Gillenwater SR, Martinez Galvis NP. Legally lethal kratom: a herbal supplement with overdose potential. <span><span class="ref-journal">J Psychoactive Drugs. </span>2019;<span class="ref-vol">51</span>:28–30.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30620247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30620247</span></a>]<div>
|
|
<i>(36 year old man took an overdose of kratom [500 grams!] and was found unarousable with agonal breathing and hypotension, laboratory testing showing ALT 3717 U/L [no bilirubin, Alk P or INR given] and 7-hydroxymitragynine in the urine, recovering with intensive care unit management).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.antony.2019.e546">Antony A, Lee TP. Herb-induced liver injury with cholestasis and renal injury secondary to short-term use of Kratom (Mitragyna speciosa). <span><span class="ref-journal">Am J Ther. </span>2019;<span class="ref-vol">26</span>:e546–e547.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29927773" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29927773</span></a>]<div>
|
|
<i>(70 year old man developed fatigue and nausea followed by jaundice shortly after taking kratom daily for 4 days for pain [at least a week after onset, bilirubin was 33.7 mg/dL, ALT 59 U/L, Alk P 230 U/L], with slow recovery, all liver test values being normal 3 months later).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Kratom.REF.schimmel.2020.263">Schimmel J, Dart RC. Kratom (Mitragyna Speciosa) liver injury: a comprehensive review. <span><span class="ref-journal">Drugs. </span>2020;<span class="ref-vol">80</span>:263–83.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31919755" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31919755</span></a>]<div>
|
|
<i>(Review of 85 cases of kratom associated liver injury from published literature, abstracts from scientific meetings, reports to the FDA and internet sources, states that the average latency is 21 days, the typical pattern is cholestatic or mixed, but that the frequency, risk factors, pathogenesis and optimal management are unclear).</i>
|
|
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548231_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">April 3, 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Kratom. [Updated 2020 Apr 3].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Khat/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Labetalol/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobKratomTc"><div id="Kratom.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548231/table/Kratom.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Kratom.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Kratom.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Kratom.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Kratom.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Kratom.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Kratom.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kratom</td><td headers="hd_h_Kratom.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S900005870</td><td headers="hd_h_Kratom.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Herbal mixture</td><td headers="hd_h_Kratom.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not applicable</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|